Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 24, Issue 5, 2009, Pages 1506-1523

  Covic, Adrian ^a,e   Kothawala, Prajesh ^b   Bernal, Myriam ^b   Robbins, Sean ^c   Chalian, Arpi ^b   Goldsmith, David ^d  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b CERNER CORPORATION   (United States)

^c AMGEN INC   (United States)

^d GUY S HOSPITAL   (United Kingdom)

^e C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

Author keywords

Chronic kidney disease; Dialysis; Mineral metabolism disturbances; Risk of cardiovascular mortality; Risk of mortality

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHORUS;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COCHRANE LIBRARY; CONGESTIVE HEART FAILURE; EMBASE; HEART INFARCTION; HUMAN; MEDLINE; METABOLIC DISORDER; METHODOLOGY; MINERAL METABOLISM; MORTALITY; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; SYSTEMATIC REVIEW;

CALCIUM; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; MINERALS; PHOSPHORUS; RISK FACTORS;

EID: 65249160167     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn613     Document Type: Review

References (86)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047
2. Meguid EN, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-340
3. United States Renal Data Systems. USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007
4. European Renal Association-European Dialysis Transplant Association Annual Data Report 2005
5. Daly C. Is early chronic kidney disease an important risk factor for cardiovascular disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrol Dial Transplant 2007; 22(Suppl 9): ix19-ix25
6. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
7. Foley RN, Murray AM, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495
8. United States Renal Data Systems. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005
9. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169
10. Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med 2004; 351: 1344-1346
11. Locatelli F, Pozzoni P, Tentori F et al. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant 2003; 18(Suppl 7): vii2-vii9
12. Menon V, Gul A, Sarnak MJ. Cardiovascular risk factors in chronic kidney disease. Kidney Int 2005; 68: 1413-1418
13. Kalantar-Zadeh K, Block G, Humphreys MH et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808
14. Zehnder D, Landray MJ, Wheeler DC et al. Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study. Nephron Clin Pract 2007; 107: c109-c116
15. Wei M, Taskapan H, Esbaei K et al. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? Int Urol Nephrol 2006; 38: 739-743
16. Al Aly Z, Gonzalez EA, Martin KJ et al. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol 2004; 24: 422-426
17. Davenport A, Crabtree J, Androjna C et al. Tumour necrosis factor does not increase during routine cuprophane haemodialysis in healthy well-nourished patients. Nephrol Dial Transplant 1991; 6: 435-439
18. Vandenbroucke JP, von Elm E, Altman DG et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007; 147: W163-W194
19. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
20. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
21. Chang JJ, Concato J, Wells CK et al. Prognostic implications of clinical practice guidelines among hemodialysis patients. Hemodial Int 2006; 10: 399-407
22. Foley RN, Parfrey PS, Harnett JD et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 1996; 16: 386-393
23. Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
24. Jassal SV, Douglas JF, Stout RW. Prognostic markers in older patients starting renal replacement therapy. Nephrol Dial Transplant 1996; 11: 1052-1057
25. Kalantar-Zadeh K, Kuwae N, Regidor DL et al.Survival predictability of time-varying indicators of bone disease in maintenance hemodial-ysis patients. Kidney Int 2006; 70: 771-780
26. KestenbaumB,Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528
27. Kimata N, Albert JM, Akiba T et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int 2007; 11: 340-348
28. Leggat JE Jr, Orzol SM, Hulbert-Shearon TE et al. Noncompliance in hemodialysis: predictors and survival analysis. Am J Kidney Dis 1998; 32: 139-145
29. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482
30. Melamed ML, Eustace JA, Plantinga L et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351-357
31. Menon V, Greene T, Pereira AA et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 2005; 46: 455-463
32. Noordzij M, Korevaar JC, Boeschoten EW et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005; 46: 925-932
33. Port FK, Pisoni RL, Bragg-Gresham JL et al. DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif 2004; 22: 175-180
34. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA et al. Mild hy-perphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005; 46: 68-77
35. Saran R, Bragg-Gresham JL, Rayner HC et al. Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int 2003; 64: 254-262
36. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16: 1788-1793
37. Stevens LA, Djurdjev O, Cardew S et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779
38. Voormolen N, Noordzij M, Grootendorst DC et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007; 22: 2909-2916
39. Tentori F, Hunt WC, Rohrscheib M et al. Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization? J Am Soc Nephrol 2007; 18: 2377-2384
40. Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44(Suppl 2): 34-38
41. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187
42. Frimat L, Loos-Ayav C, Panescu V et al. Early referral to a nephrolo-gist is associated with better outcomes in type 2 diabetes patients with end-stage renal disease. Diabetes Metab 2004; 30: 67-74
43. Bommer J, Locatelli F, Satayathum S et al. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 661-671
44. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456
45. Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodial-ysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865
46. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125
47. Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800
48. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137
49. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441
50. Noordzij M, Korevaar JC, Bos WJ et al. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients. Nephrol Dial Transplant 2006; 21: 2513-2520
51. Kato A, Takita T, Furuhashi M et al. Association between seropreva-lenceofanti-chlamydial antibodies and long-termcardiovascular mortality in chronic hemodialysis patients. Atherosclerosis 2006; 188: 120-125
52. Marco MP, Craver L, Betriu A et al. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int Suppl 2003; 85: S111-S114
53. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187
54. Pool PE, Seagren SC, Salel AF. Metabolic consequences of treating hypertension. Am J Hypertens 1991; 4(Pt 2): 494S-502S
55. Shoji T, Shinohara K, Kimoto E et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184
56. Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlatesof congestive heartfailure among incident US dialysis patients. Am J Kidney Dis 2001; 38: 992-1000
57. Nakai S, Akiba T, Kazama J et al. Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 2008; 12: 49-54
58. TonelliM, Sacks F, Pfeffer M et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633
59. Dhingra R, Sullivan LM, Fox CS et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885
60. Raggi P, Kleerekoper M. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3(3): 836-843
61. Tentori F, Blayney MJ, Albert JM et al. Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52(3): 519-530
62. Shanahan CM. Inflammation ushers in calcification: a cycle of damage and protection? Circulation 2007; 116: 2782-2785
63. Ketteler M, Westenfeld R, Schlieper G et al. Pathogenesis of vascular calcification in dialysis patients. Clin Exp Nephrol 2005; 9: 265-270
64. Lomashvili KA, Cobbs S, Hennigar RA et al. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol 2004; 15: 1392-1401
65. Lomashvili KA, Garg P, Narisawa S et al. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int 2008; 73: 1024-1030
66. Gusbeth-Tatomir P, Covic A. Causes and consequences of increased arterial stiffness in chronic kidney disease patients. Kidney Blood Press Res 2007; 30: 97-107
67. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003; 14(Suppl 4): S305-S309
68. Budoff MJ, Shaw LJ, Liu ST et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol 2007; 49: 1860-1870
69. Amann K, Ritz E, Wiest G et al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994; 4: 1814-1819
70. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383-392
71. Kosch M, Hausberg M, Vormbrock K et al. Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyper-parathyroidism improves after parathyroidectomy. Cardiovasc Res 2000; 47: 813-818
72. Saleh FN, Schirmer H, Sundsfjord J et al. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003; 24: 2054-2060
73. Zittermann A, Schleithoff SS, Tenderich G et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003; 41: 105-112
74. Watson KE, Abrolat ML, Malone LL et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997; 96: 1755-1760
75. Li YC, Kong J, Wei M et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238
76. Xiang W, Kong J, Chen S et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125-E132
77. Koch M, Lund R, Oldemeyer B et al. Refeeding hypophosphatemia in a chronically hyperphosphatemic hemodialysis patient. Nephron 2000; 86: 552
78. de Francisco AL. Secondary hyperparathyroidism: review of the disease and its treatment. Clin Ther 2004; 26: 1976-1993
79. Henrich WL, Hunt JM, Nixon JV. Increased ionized calcium and left ventricular contractility during hemodialysis. N Engl J Med 1984; 310: 19-23
80. Lee DT, Yu DS, Woo J et al. Health-related quality of life in patients with congestive heart failure. Eur J Heart Fail 2005; 7: 419-422
81. Haacke C, Althaus A, Spottke A et al. Long-termoutcome after stroke: evaluating health-related quality of life using utility measurements. Stroke 2006; 37: 193-198
82. Gal-Moscovici A, Sprague SM, Hutchison AJ et al. Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed? Semin Dial 2007; 20: 24-32
83. Chertow GM, Pupim LB, Block GA et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007; 2: 898-905
84. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. Br Med J 1994; 309: 1351-1355
85. Easterbrook PJ, Berlin JA, Gopalan R et al. Publication bias in clinical research. Lancet 1991; 337: 867-872
86. Chalmers I. Underreporting research is scientific misconduct. JAMA 1990; 263: 1405-1408